ALDX: Aldeyra Therapeutics, Inc.
About
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
Current Value
$4.891 Year Return
Current Value
$4.891 Year Return
Key Details
Market Cap
$294.18M
P/E Ratio
-6.55
1Y Stock Return
102.46%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
3.5
Strategies that include ALDX
Stock's related to ALDX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VSTO | 49.61% | $2.58B | +71.61% | 0.00% |
| CLLS | 47.78% | $141.30M | -30.99% | 0.00% |
| SMG | 45.78% | $4.24B | +35.01% | 3.52% |
| CRSP | 45.44% | $4.01B | -30.49% | 0.00% |
| FOLD | 44.63% | $2.84B | -11.52% | 0.00% |
| HROW | 43.20% | $1.41B | +330.59% | 0.00% |
| ACLX | 41.64% | $4.74B | +69.19% | 0.00% |
| HCAT | 40.80% | $458.79M | 0.00% | 0.00% |
| TGTX | 40.60% | $4.72B | +146.10% | 0.00% |
| DOCN | 40.45% | $3.51B | +33.83% | 0.00% |
| VSAT | 39.61% | $876.93M | -65.78% | 0.00% |
| BBIO | 39.56% | $4.26B | -20.38% | 0.00% |
| CPRX | 39.20% | $2.55B | +55.68% | 0.00% |
| APPS | 38.84% | $125.51M | -75.85% | 0.00% |
| CRNX | 38.71% | $5.12B | +84.27% | 0.00% |
| CLFD | 38.26% | $398.66M | +4.48% | 0.00% |
| CYRX | 37.79% | $342.80M | -48.82% | 0.00% |
| RCUS | 37.70% | $1.33B | +5.07% | 0.00% |
| RDNT | 37.67% | $5.91B | +151.89% | 0.00% |
| PRA | 37.58% | $830.78M | +27.17% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HIMX | <0.01% | $913.68M | -13.98% | 5.58% |
| GYRE | -<0.01% | $1.21B | +1.49% | 0.00% |
| MDLZ | -0.01% | $85.41B | -10.00% | 2.73% |
| DMLP | -0.03% | $1.58B | +18.00% | 10.54% |
| GL | -0.04% | $9.18B | -8.60% | 0.86% |
| CLB | -0.05% | $929.61M | +8.55% | 0.20% |
| BACK | -0.05% | $1.76M | -32.90% | 0.00% |
| MRO | 0.05% | $16.08B | +13.59% | 1.53% |
| THG | 0.06% | $5.88B | +36.24% | 2.08% |
| VITL | 0.06% | $1.32B | +142.79% | 0.00% |
| MCD | -0.07% | $208.34B | +3.66% | 2.30% |
| RRGB | 0.09% | $82.67M | -42.73% | 0.00% |
| AON | -0.10% | $82.00B | +16.33% | 0.70% |
| KDP | -0.11% | $42.76B | -1.22% | 2.77% |
| SO | 0.13% | $96.74B | +26.76% | 3.24% |
| K | -0.14% | $27.77B | +52.50% | 2.79% |
| SYPR | 0.15% | $32.23M | -26.32% | 0.00% |
| EG | 0.16% | $15.92B | -8.98% | 2.02% |
| TX | -0.17% | $6.57B | -12.10% | 9.26% |
| WRB | 0.17% | $22.94B | +29.98% | 0.69% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CNSL | -39.78% | $548.51M | +9.98% | 0.00% |
| UNM | -26.91% | $13.16B | +69.20% | 2.16% |
| PAYC | -26.52% | $12.12B | +21.78% | 0.69% |
| MCK | -21.91% | $78.15B | +35.51% | 0.42% |
| FDP | -19.41% | $1.62B | +45.67% | 2.97% |
| BTCT | -17.25% | $42.61M | +353.33% | 0.00% |
| EL | -14.54% | $23.26B | -46.08% | 4.10% |
| ADP | -13.06% | $121.23B | +28.69% | 1.89% |
| ALL | -10.95% | $52.06B | +45.67% | 1.85% |
| HUSA | -10.56% | $16.69M | -11.56% | 0.00% |
| GPRE | -10.50% | $682.07M | -57.68% | 0.00% |
| PRPO | -10.21% | $9.10M | -13.65% | 0.00% |
| GHI | -10.06% | $272.26M | -27.60% | 12.75% |
| CI | -9.27% | $89.70B | +12.57% | 1.68% |
| MNST | -9.24% | $52.25B | -1.95% | 0.00% |
| ASPS | -9.20% | $22.36M | -80.26% | 0.00% |
| PCRX | -9.12% | $772.48M | -37.25% | 0.00% |
| QUAD | -8.96% | $366.66M | +43.76% | 2.84% |
| HUM | -8.12% | $33.45B | -45.22% | 1.25% |
| SBUX | -7.76% | $111.45B | -5.15% | 2.37% |
ETF's related to ALDX
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PTH | 52.82% | $143.31M | 0.6% |
| RSPA | 50.68% | $273.87M | 0% |
| XBI | 50.53% | $6.58B | 0.35% |
| IWO | 48.80% | $12.56B | 0.24% |
| IWC | 48.57% | $933.99M | 0.6% |
| ARKG | 47.57% | $1.13B | 0.75% |
| VTWO | 47.54% | $12.38B | 0.1% |
| GNOM | 47.47% | $70.59M | 0.5% |
| IWM | 47.45% | $75.73B | 0.19% |
| KOMP | 47.39% | $2.09B | 0.2% |
| PSC | 47.11% | $702.17M | 0.38% |
| VBK | 46.82% | $19.31B | 0.07% |
| ISCG | 46.67% | $640.00M | 0.06% |
| PBE | 46.34% | $258.53M | 0.58% |
| VXF | 46.16% | $21.54B | 0.06% |
| IBB | 45.91% | $6.66B | 0.45% |
| PRFZ | 45.84% | $2.65B | 0.39% |
| SMMD | 45.64% | $1.24B | 0.15% |
| ARKK | 45.59% | $6.28B | 0.75% |
| IJT | 45.16% | $6.64B | 0.18% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BCI | 0.11% | $1.20B | 0.26% |
| IBHD | 0.19% | $327.80M | 0.35% |
| DBC | 0.44% | $1.39B | 0.87% |
| HDRO | -0.47% | $164.26M | 0.3% |
| BCD | 0.49% | $245.02M | 0.3% |
| CSHI | -0.83% | $482.85M | 0.38% |
| TBLL | 0.96% | $1.92B | 0.08% |
| CMDY | 1.19% | $279.14M | 0.28% |
| DBMF | -1.20% | $1.02B | 0.85% |
| PDBC | -1.24% | $4.40B | 0.59% |
| FLBL | -1.49% | $645.58M | 0.45% |
| GSG | -1.52% | $914.42M | 0.75% |
| IYK | -1.63% | $1.30B | 0.4% |
| COMT | -1.68% | $829.06M | 0.48% |
| MINT | -1.69% | $11.62B | 0.35% |
| FTGC | -1.70% | $2.17B | 1.02% |
| GCC | 2.11% | $133.23M | 0.55% |
| AGZD | -2.23% | $142.76M | 0.23% |
| CCOR | -2.33% | $109.04M | 1.18% |
| FLRT | 2.54% | $401.26M | 0.6% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -41.03% | $388.04M | 1.43% |
| VIXY | -27.77% | $195.31M | 0.85% |
| USDU | -19.67% | $201.97M | 0.5% |
| UUP | -18.71% | $309.25M | 0.77% |
| TAIL | -17.61% | $67.98M | 0.59% |
| CTA | -15.67% | $350.27M | 0.78% |
| EQLS | -10.66% | $76.08M | 1% |
| KRBN | -8.81% | $242.47M | 0.85% |
| UNG | -8.54% | $908.80M | 1.06% |
| DBO | -7.81% | $217.57M | 0.77% |
| DBE | -7.44% | $50.13M | 0.77% |
| SEIX | -6.99% | $268.81M | 0.62% |
| HIGH | -6.79% | $302.78M | 0.51% |
| FMF | -6.73% | $244.61M | 0.95% |
| CORN | -6.70% | $61.12M | 0.2% |
| SOYB | -6.40% | $27.32M | 0.22% |
| WEAT | -6.13% | $120.27M | 0.28% |
| KMLM | -5.90% | $353.87M | 0.9% |
| DBA | -5.34% | $755.88M | 0.93% |
| XHLF | -4.95% | $874.27M | 0.03% |
News
Yahoo
As the U.S. stock market shows signs of a modest recovery, with major indices inching higher ahead of key earnings reports, investors are keenly observing smaller sectors for potential opportunities. Penny stocks, despite their somewhat outdated moniker, continue to attract attention as they often represent emerging companies that could offer growth at lower entry points. This article explores three penny stocks that stand out for their financial resilience and potential to provide compelling...
Yahoo
The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.
Finnhub
By Connor Hart Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review....
Yahoo
LEXINGTON, Mass., November 18, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025. In conjunction with the acceptance of the NDA for
Finnhub
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement PDUFA Date is April 2,...
Yahoo
LEXINGTON, Mass., November 14, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference 2024. The conference is being conducted in London, England November 19- 21, 2024.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.